Volume 2, Issue 1, March 2020, Pages 35 - 39
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
Kristian T. Andersen1, *, Maja Hinge1, Agoston Gyula Szabo1, Erik Segel2, Tina Ormstrup3, Paw C. Holdgaard4, Niels Pallisgaard5, Gitte Kerndrup6, Torben Plesner1
1Department of Medicine, Division of Hematology, Lillebælt Hospital, Vejle, Denmark; Department of Regional Health Research (IRS) at the University of Southern Denmark (SDU), Odense, Denmark
2Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
3Department of Radiology, Lillebælt Hospital, Vejle, Denmark
4Department of Nuclear Medicine, Lillebælt Hospital, Vejle, Denmark
5Department of Clinical Immunology and Biochemistry, Lillebælt Hospital, Vejle, Denmark
6Department of Clinical Genetics, Lillebælt Hospital, Vejle, Denmark
*Corresponding author. Email: Kristian.Thidemann.Andersen@rsyd.dk
Kristian T. Andersen
Received 4 October 2019, Accepted 15 January 2020, Available Online 26 January 2020.
- 10.2991/chi.d.200116.001How to use a DOI?
- Multiple myeloma; Clinical trial; Hematology; First line therapy
- © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Kristian T. Andersen AU - Maja Hinge AU - Agoston Gyula Szabo AU - Erik Segel AU - Tina Ormstrup AU - Paw C. Holdgaard AU - Niels Pallisgaard AU - Gitte Kerndrup AU - Torben Plesner PY - 2020 DA - 2020/01/26 TI - Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma JO - Clinical Hematology International SP - 35 EP - 39 VL - 2 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.200116.001 DO - 10.2991/chi.d.200116.001 ID - Andersen2020 ER -